pirtobrutinib
eli lilly
['leusm', 'oval,(-approval)', 'cll']
join us for our oral presentation at #eha2022! we re sharing updated results from the phase 1/2 bruin study, evaluating a highly selective, reversible (non-covalent) #btki in previously treated cll/sll. view presentation details here: #cll #leusm 
Dedicated to communicating the latest science & innovation from Loxo@Lilly. Tweets intended for US oncology HCPs. See our community guidelines: https://t.co/1q8vAe63mK